Thalassaemia Treatment in India – Curative Bone Marrow Transplant
Thalassaemia treatment in India from $15,000. Curative BMT for thalassaemia major. India leads global BMT volumes for thalassaemia with 90%+ success rates. Book now.
Estimated cost: $15,000 – $25,000 · Average stay: 30–45 days
Thalassaemia is an inherited blood disorder in which abnormal haemoglobin leads to severe anaemia requiring lifelong blood transfusions every 2–4 weeks. Iron overload from repeated transfusions damages the heart, liver, and endocrine glands over time.
The only curative treatment is haematopoietic stem-cell transplantation (HSCT) — replacing the defective bone marrow with healthy donor marrow. India performs more thalassaemia bone marrow transplants than almost any other country, with survival rates exceeding 90% in Class I patients at specialist centres.
At $15,000–$25,000, India offers curative thalassaemia BMT at 85–90% lower cost than the US ($200,000–$400,000), making it the leading global destination for cost-effective curative treatment.
What is Thalassaemia?
Beta-thalassaemia major — the most severe form — is caused by mutations in both beta-globin genes, resulting in virtually no functional haemoglobin production. Without treatment, children develop severe anaemia, failure to thrive, and skeletal deformities from compensatory marrow expansion. Regular blood transfusions sustain life but cause progressive iron overload requiring concurrent chelation therapy.
BMT replaces the patient's defective bone marrow with healthy donor marrow, which then permanently produces normal haemoglobin. The Pesaro classification (Class I, II, III) predicts BMT outcomes based on liver size, fibrosis stage, and chelation therapy compliance — Class I patients achieve the best results.
Who is Eligible for Thalassaemia BMT?
BMT is offered to all patients with thalassaemia major who have a suitable donor. Pesaro Class I patients — good chelation compliance, no liver damage, normal liver size, typically under 10 years — achieve the best outcomes (90–95% thalassaemia-free survival). Class II patients achieve 80–85%. Class III (poor compliance, liver fibrosis, enlarged liver) have lower success rates but still benefit from early transplant evaluation. Age alone is not a contraindication — adults with thalassaemia major can be transplanted with reduced-intensity conditioning.
How is Thalassaemia BMT Performed?
Pre-transplant evaluation includes HLA typing of patient and all siblings, organ function assessment (cardiac echo, LFTs, fibroscan), serum ferritin, and liver MRI T2* for iron quantification. Sibling donors are preferred; matched unrelated donors (MUD) from international registries are used when siblings are unavailable.
Conditioning uses the Pesaro protocol: busulfan and cyclophosphamide. Stem cells are infused and engraftment confirmed at day 20–30. Post-transplant immunosuppression with cyclosporine and short-course methotrexate prevents rejection. Blood transfusions support until haemoglobin self-sustains at around day 20–35. Successful engraftment permanently eliminates the need for transfusions.
Procedure Steps
- Thalassaemia confirmation: HPLC, beta-globin gene sequencing
- Pesaro Class assignment (I, II, III) based on liver size, fibrosis, chelation adherence
- HLA typing of patient, all siblings, and parents for donor matching
- Pre-transplant organ function: LFTs, cardiac echo, PFTs, ferritin, liver MRI T2*
- Conditioning: busulfan + cyclophosphamide (Pesaro protocol) or RIC for Class III
- Stem cell infusion: matched sibling donor bone marrow or PBSC
- Daily CBC monitoring; chimerism testing at day +14, +28, +100
- Post-transplant immunosuppression: cyclosporine + short-course methotrexate
- Transfusion support until haemoglobin self-sustains
- Iron chelation continued post-BMT until ferritin normalises at 6–18 months
Cost Comparison Worldwide
Country — Range — Savings
--- — --- — ---
India — $15,000 – $25,000 — Save 93%
UAE — $100,000 – $200,000 — Save 87%
United States — $200,000 – $400,000 — —
United Kingdom — $150,000 – $300,000 — —
India performs the highest volume of thalassaemia BMT globally at 85–93% lower cost than the US. All figures include conditioning, stem-cell infusion, 30–45-day hospital stay, and initial post-transplant monitoring. India is the undisputed global leader for cost-effective curative thalassaemia BMT.
Recovery & Follow-up
Engraftment occurs at day 20–35 — marked by rising blood counts that become self-sustaining. Most patients can stop blood transfusions within 4–6 weeks. Iron chelation continues for 6–18 months until excess iron stores are cleared. Total hospital stay is 40–60 days; outpatient follow-up for a further 30–60 days before returning home.
Recovery Tips
- Continue iron chelation therapy as prescribed post-BMT — iron overload is cleared slowly and chelation is essential.
- Attend all chimerism monitoring and blood count appointments — early detection of mixed chimerism allows intervention before relapse.
- Avoid live vaccines for at least 6 months post-BMT while immunosuppressed.
- Growth and endocrine function should be monitored annually — BMT-related hormonal effects can occur in young patients.
- Maintain routine dental hygiene — infection prevention is critical in the first year post-BMT.
Risks & Complications
Primary risks include graft rejection (5–10% in MUD and haploidentical transplants), graft-versus-host disease (GVHD), infection (bacterial, viral, fungal), and veno-occlusive disease of the liver from conditioning. Modern prophylaxis protocols and experienced BMT teams minimise all these risks. Long-term risks include endocrine effects from conditioning and iron overload monitoring requirements.
Why GAF Healthcare
Gaf Healthcare plans complete thalassaemia BMT journeys from pre-travel gene mutation analysis coordination to early HLA typing of all siblings, hospital listing at India's specialist thalassaemia BMT centres, family accommodation near the unit, and lifelong surveillance planning for post-transplant care back home.
Frequently Asked Questions
At what age is thalassaemia BMT most successful?
BMT in Pesaro Class I patients — typically under 10 years old — achieves thalassaemia-free survival of 90–95%. Class II achieves 80–85%. Earlier transplant gives better results by avoiding progressive iron overload organ damage.
What if no sibling donor is available?
Matched unrelated donors from international registries (DKMS, NMDP) and haploidentical parent donors using post-transplant cyclophosphamide are viable options with improving outcomes at experienced Indian centres.
Will my child still need blood transfusions after a successful BMT?
No. A successful BMT with full donor chimerism eliminates the need for transfusions. Most patients stop transfusions within 4–6 weeks of transplant.
Is gene therapy available for thalassaemia?
Gene therapy (betibeglogene altarvovec — Zynteglo) is approved in the US and Europe but costs $2.8 million. Clinical trials are active in India. Currently, allogeneic BMT remains the most accessible curative option.
How long will my child need to stay in India?
Plan for 40–60 days in hospital plus 30–60 days of outpatient follow-up nearby. Total India stay is typically 2–3 months for uncomplicated cases. We arrange full family accommodation and support.